Havemeyer Place LP Makes New $1.30 Million Investment in Eli Lilly and Company $LLY

Havemeyer Place LP bought a new position in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,209 shares of the company’s stock, valued at approximately $1,299,000.

Other institutional investors also recently modified their holdings of the company. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Miller Global Investments LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $33,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the period. Dorato Capital Management acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $36,000. Finally, New England Capital Financial Advisors LLC grew its position in shares of Eli Lilly and Company by 142.9% during the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock worth $37,000 after buying an additional 20 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,285.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 6th. Argus lifted their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Finally, UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

Eli Lilly and Company Stock Up 0.2%

Shares of NYSE LLY opened at $1,133.15 on Monday. The stock has a market cap of $1.07 trillion, a P/E ratio of 40.25, a P/E/G ratio of 1.24 and a beta of 0.53. The firm has a 50 day moving average price of $974.59 and a 200 day moving average price of $1,012.96. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,166.29.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.